您好，欢迎来到半岛电竞官方网址 ！ [ 登录] [ 免费注册]
半岛电竞官方网址
发布求购
位置： 首页> 半岛bd体育手机客户端 库> Itolizumab
立即咨询
咨询类型：
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
Itolizumab
本半岛bd体育手机客户端 不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
CAS NO: 1116433-11-4
包装与价格：
包装 价格(元)
1mg 电议
5mg 电议

半岛bd体育手机客户端 名称
Anti-Human CD6 Recombinant Antibody
半岛bd体育手机客户端 介绍
Itolizumab (Anti-Human CD6 Recombinant Antibody) 是一种人源化重组 抗 CD6单克隆抗体 (MAb)，靶向 CD6 的细胞外 SRCR 远端结构域 1。Itolizumab 可减少 T 细胞增殖并抑制促炎细胞因子的产生，例如 INF-γ、TNFα 和 IL-6。Itolizumab 可用于银屑病、类风湿性关节炎 (RA)、COVID-19 的研究。
生物活性

Itolizumab (Anti-HumanCD6Recombinant Antibody) is a humanized recombinantanti-CD6monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 ofCD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα andIL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].
IC50& Target

CD6[1]
体外研究
(In Vitro)

Itolizumab (100 μg/mL) inhibits T cell proliferation[4].
Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs[4].
Itolizumab (40 μg/mL) reduces CD26hiCD161+ CD8+ T cells during culture of PBMCs overnight[5].
Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions[6].
体内研究
(In Vivo)

Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD)[7].

Animal Model: Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)[7]
Dosage: 60 μg or 300μg
Administration: Intraperitoneal injection (i.p.), prior to PBMC transplantation.
Result: Decreased mortality compared to the vehicle (100% vs. 10%).
CAS 号

1116433-11-4
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Baidu
map